Clinical trials: Maximum Tolerated Dose
Depression
Trial to Determine the Maximum Tolerated Dose (MTD) Based on Safety and Tolerability, of Org 26576 in Participants With Major Depressive Disorder (174001/P05704/MK-8777-001)
Trial to determine the maximum tolerated dose (MTD) based on safety and tolerability of MK-8777 (Org 26576, SCH 900777) in participants with major depressive disorder.
- Trial name
- NCT00610649
- Testing
- MK-8777
- Volunteers
- 54 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Solid Tumors
A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors
Researchers are looking for a better way to treat people who have advanced solid tumors. Advanced solid tumors are types of cancer that may have spread to nearby tissue, lymph nodes, and/or to distant parts of the body and that…
- Trial name
- NCT05614102
- Testing
- BAY2965501, Pembrolizumab, Platinum-based Chemotherapy
- Where
- 21 sites in United States, Belgium and 5 more
- Volunteers
- 284 people
- Sponsor
- Bayer
Solid Tumors
Phase I Study of BAY1436032 in IDH1-mutant Advanced Solid Tumors
The primary objective of this study is: Determine the safety, tolerability, maximum tolerated dose (MTD) or recommended Phase II dose (RP2D) of BAY 1436032 in patients with isocitrate dehydrogenase-1 (IDH1)-R132X-mutant advanced…
- Trial name
- NCT02746081
- Testing
- BAY1436032
- Where
- 13 sites in United States, Denmark and 2 more
- Volunteers
- 81 people
- Sponsor
- Bayer
Solid Tumor, Adult, Squamous Cell Carcinoma of Head and Neck
A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer
This is a phase 1/2, multi-center study with an open-label, dose escalation phase followed by a single-arm expansion phase to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of NT219 alone and in…
- Conditions
- Solid Tumor, Adult, Squamous Cell Carcinoma of Head and Neck, Colorectal Adenocarcinoma, Metastatic Solid Tumor
- Trial name
- NCT04474470
- Testing
- NT219, NT219 and ERBITUX® - Dose Escalation, NT219 and ERBITUX® - Expansion
- Where
- 10 sites in United States, Israel
- Volunteers
- 52 people
- Sponsor
- TyrNovo Ltd.
Lymphoma, Sarcoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory of Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Background: Vorinostat and bortezomib are anti-tumor drugs that have been approved by the Food and Drug Administration to treat different kinds of myeloma and lymphoma in adults.
- Conditions
- Lymphoma, Sarcoma, WilmsTumor, Neuroblastoma
- Trial name
- NCT01132911
- Testing
- Vorinostat (SAHA), Velcade (PS-341, Bortezomib)
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Neoplasms
Clinical Study to Evaluate the Maximum Tolerated Dose of BAY87-2243 in Patients With Advanced Malignancies
This is the first study of this drug in human beings. Every patient will receive the drug, there is no placebo group. Patients with advanced tumors will be treated.
- Trial name
- NCT01297530
- Testing
- BAY87-2243
- Where
- 3 sites in Germany, Norway and 1 more
- Volunteers
- 5 people
- Sponsor
- Bayer
Breast Cancer
Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)
The goal of this clinical research study is to find the highest tolerable dose of seliciclib that can be given in combination with liposomal doxorubicin to patients with metastatic breast cancer.
- Trial name
- NCT01333423
- Testing
- Liposomal Doxorubicin, Seliciclib
- Sponsor
- M.D. Anderson Cancer Center
Cervix Cancer
CAmpto-CISplatine Plus Radiotherapy in Advanced Cervix Cancer : Search of Tolerated Maximum Dose of Campto
Search of maximum tolerated irinotecan dose in association with cisplatin and pelvic radiotherapy in patients with an advanced cervix cancer.
- Trial name
- NCT00251888
- Testing
- campto (irinotecan), cisplatin (cisplatyl)
- Where
- 2 sites in France
- Volunteers
- 15 people
- Sponsor
- ARCAGY/ GINECO GROUP
Head and Neck Cancer
Open Label, Phase I ZD6474 Head and Neck Cancer Study
The purpose of this study is to determine the maximum tolerated dose of ZD6474 given in combination with radiation or in combination with chemotherapy and radiation in patients with squamous cell carcinoma of the head and neck.
- Trial name
- NCT00450138
- Testing
- ZD6474 (vandetanib), Cisplatin, Radiation
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- Sanofi
Solid Tumor, Renal Cell Cancer Metastatic
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
Phase 1 (Dose Escalation) of this study will assess the safety, tolerability, dose-limiting toxicity (DLT), and will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of EU101 in participants with…
- Conditions
- Solid Tumor, Renal Cell Cancer Metastatic, Non-Small Cell Lung Cancer, Renal Cell Carcinoma
- Trial name
- NCT04903873
- Testing
- EU101
- Where
- 6 sites in United States, South Korea
- Volunteers
- 110 people
- Sponsor
- Eutilex
Lymphoma, Small Intestine Cancer
Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00005639
- Testing
- Azacitidine Injection, sodium phenylbutyrate
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Gastric Carcinoma
Dose Escalation Study of Liposomal Paclitaxel With/Without Capecitabine in Patients With Advanced Gastric Carcinoma
The purpose of this study is to investigate the maximum tolerated dose and pharmacokinetics of liposomal paclitaxel with/without capecitabine in Chinese cancer patients with advanced gastric carcinoma.
- Trial name
- NCT00639522
- Testing
- Liposomal paclitaxel and capecitabine
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Nanjing Sike Pharmaceutical Co., Ltd.
Glioblastoma Multiforme
A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Temozolomide in Patients with Recurrent or Progressive Glioblastoma Multiforme (GBM)
This is a Phase 1 study to evaluate the maximum tolerated dose, safety and efficacy of BEY1107 in combination with Temozolomide in Patients with Recurrent or Progressive Glioblastoma Multiforme (GBM)
- Trial name
- NCT05769660
- Testing
- BEY1107, Temozolomide
- Where
- South Korea
- Volunteers
- 12 people
- Sponsor
- BeyondBio Inc.
Medical Oncology
Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors
Determine the safety, tolerability and maximum tolerated dose of anetumab ravtansine (BAY 94-9343) in combination with pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 in subjects with mesothelin-expressing predominantly epithelial…
- Trial name
- NCT02639091
- Testing
- BAY 94-9343, Pemetrexed, Cisplatin
- Where
- 6 sites in United States, Italy
- Volunteers
- 36 people
- Sponsor
- Bayer
Multiple Myeloma
MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma
The purpose of this study is to determine the maximum tolerated dose and effectiveness of the study drug (CC-4047) Alone Or in Combination With Low-dose Dexamethasone as treatment for patients with relapsed and refractory…
- Trial name
- NCT00833833
- Testing
- Pomalidomide, Dexamethasone, Aspirin
- Where
- 19 sites in United States, Canada
- Volunteers
- 259 people
- Sponsor
- Celgene Corporation
Superficial Basal Cell Carcinoma
To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC
The purpose of this study is to determine maximum tolerated dose level (MTD) of PEP005 Topical Gel for the treatment of superficial basal cell carcinoma on the trunk
- Trial name
- NCT00432185
- Testing
- PEP005
- Where
- 9 sites in United States
- Volunteers
- 117 people
- Sponsor
- Peplin
Glioblastoma, Adult Gliosarcoma
Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients
This is a phase I trial evaluating the maximum tolerated dose, safety and efficiency of Mesenchymal stem cells into which the suicide gene, cytosine deaminase (CD), injected into the resection cavity of patients with recurrent…
- Conditions
- Glioblastoma, Adult Gliosarcoma, Neoplasms, Brain, Neoplasms, Germ Cell and Embryonal
- Trial name
- MSC11FCD-GBM (NCT04657315)
- Testing
- MSC11FCD
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- CHA University
Advanced Solid Tumor, Lung Cancer
Carbon Nanoparticle-Loaded Iron [CNSI-Fe(II)] in the Treatment of Advanced Solid Tumor
This Phase I clinical trial aims to evaluate the safety, tolerability, pharmacokinetics (PK) profile and preliminary efficacy of intratumoral injection of Carbon Nanoparticle-Loaded Iron [CNSI-Fe(II)] in patients with advanced…
- Conditions
- Advanced Solid Tumor, Lung Cancer, Pancreas Cancer, Breast Cancer
- Trial name
- CNSI-Fe(II) (NCT06048367)
- Testing
- CNSI-Fe(II) 30 mg, CNSI-Fe(II) 60 mg, CNSI-Fe(II) 90 mg
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Sichuan Enray Pharmaceutical Sciences Company
Cancer
Open-Label Study to Determine the Maximum Tolerated Oral Dose of the Kinase Inhibitor CEP-11981 in Patients With Advanced Cancer
The primary objective of this study is to determine the maximum tolerated dose (MTD) and dose-limiting toxicities of CEP-11981 in patients with advanced, relapsed/refractory solid tumors.
- Trial name
- NCT00875264
- Testing
- CEP-11981 (kinase inhibitor)
- Volunteers
- 43 people
- Sponsor
- Cephalon
Neoplasm Metastasis, Gastric Cancer
Safety Study of GC1118 (Recombinant Human Anti-EGFR Antibody) in Patients With Advanced Solid Cancer
The purpose of this study is to determine the maximum tolerated dose(MTD)/Recommended Phase 2 Dose(RP2D) and to evaluate the safety and tolerability of GC1118 when given by intravenous (IV) infusion to patients with stage IV…
- Conditions
- Neoplasm Metastasis, Gastric Cancer, Colorectal Cancer
- Trial name
- NCT02352571
- Testing
- GC1118
- Where
- South Korea
- Volunteers
- 72 people
- Sponsor
- Green Cross Corporation